ZIYOND PHARMA Submits Main Board Listing Application to HKEX; Ranks No.1 in China for Number of Filed & Approved Topical Dermatological Drugs
NewTimeSpace News: As disclosed by HKEX, Ziyond Pharmaceutical Co., Ltd. submitted a Main Board listing application to The Stock Exchange of Hong Kong Limited on 9 July 2026, with CITIC Securities appointed as the sole sponsor.
Ziyond Pharmaceutical is a Chinese pharmaceutical enterprise focusing on topical dermatology, delivering comprehensive solutions covering dermatological medicines and medical-grade skincare products. Per Frost & Sullivan data, the Company secures the top position in China by the aggregate count of topical dermatological drugs that have been filed and granted marketing authorisations. Its commercial portfolio covers eight major dermatological indications across China, affecting approximately 843 million prevalent cases combined in 2025.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- BE FRIENDS HLDG(01450.HK): Q2 2026 GMV Reaches Approximately RMB3.36 Billion; H1 Cumulative GMV Hits RMB6.53 Billion
- DONGJIANG ENV(00895.HK): Subsidiary Daxiang Logistics Wins Zhongnan Steel Road Transportation Tender Worth Approximately RMB18.49 Million
- ZIJIN GOLD INTL(02259.HK): Expected Net Profit of Approximately USD1.4 Billion for H1 2026, Surge of Around 169% YoY
- Daily Report on Hong Kong-Listed LLM Concept Stocks (July 9, 2026)
